Abstract 430: Pemigatinib, an FGFR inhibitor, overcomes resistance to KRASG12C inhibitors in mesenchymal-like NSCLC tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-430
Abstract: KRAS is one of the most frequently mutated oncogenes. Clinical studies with recently developed covalent KRASG12C inhibitors have shown promising anticancer activity in patients with KRASG12C tumors (substitution of glycine to cysteine at amino acid… read more here.
Keywords: expression; mesenchymal like; krasg12c inhibitors; krasg12c ... See more keywords
Abstract B035: Targeting transcriptional elongation kinases prevents adaptation to KRASG12C inhibitors in both MAPK-dependent and -independent models of acquired resistance
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-b035
Abstract: The development of covalent inhibitors targeting KRASG12C mutations offers a precision medicine approach to a large cohort of lung cancer patients previously lacking opportunities for targeted therapy. Despite promising initial responses ranging from disease control… read more here.
Keywords: acquired resistance; mapk dependent; krasg12c inhibitors; krasg12c ... See more keywords
A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14020390
Abstract: Simple Summary KRAS is the most common oncogene in human cancers and has long been considered ‘‘undruggable’’—that is, until recently, when covalent inhibitors that selectively target KRASG12C substitution were developed. The satisfactory results of multicenter… read more here.
Keywords: inhibitor; therapy; krasg12c inhibitors; krasg12c ... See more keywords
TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceuticals"
DOI: 10.3390/ph16040553
Abstract: KRASG12C is one of the most common mutations detected in non-small cell lung cancer (NSCLC) patients, and it is a marker of poor prognosis. The first FDA-approved KRASG12C inhibitors, sotorasib and adagrasib, have been an… read more here.
Keywords: cell; krasg12c inhibitors; krasg12c; mutant nsclc ... See more keywords